Ms. Haynes was with Mallinckrodt Pharmaceuticals for over 28 years.  As VP of Alliance Management, she led the divestitures of Mallinckrodt’s contrast media and nuclear imaging businesses, delivering nearly $1 billion in total transaction value. Prior roles include Vice President & General Manager where she led teams in North and South America and Global Marketing, Marketing Director, Training Manager, and Pharmacist with Board Certification in Nuclear Pharmacy.

• Education: BS Pharmacy, St. Louis College of Pharmacy; MBA, Washington University
• Boards: Board of Trustees, University of Health Sciences and Pharmacy in St. Louis; ARTMS Products, Inc.

At UMB, he was also Director of the Nanofabrication and Imaging Core Labs at the Center for Blood Oxygen Transport and Hemostasis (CBOTH). Earlier he was a tenured Associate Professor of Bioengineering and Associate Head at University of Illinois at Urbana Champaign. He brings 20 years of experience in nanotechnology, chemistry, and bioengineering. He holds 8 granted U.S. patents, 31 U.S. patent applications, numerous high impact publications, and several ongoing clinical trials and is the founder of three University- based early start-ups including Vitruvian Bio dedicated to developing novel image-guided therapies, and InnSight Technologies dedicated to nanotechnology-based application for ocular diseases. He is an elected fellow of Royal Society of Chemistry, American Heart Association and American College of Cardiology.

• Education: MS, Vidyasagar University, India, PhD, Indian Institute of Technology (ITT) India
• Research: Postdoctoral Fellowships (Karen Wooley), Washington University, St. Louis

Prior to coming to Maryland, he was an Associate Professor in Bioengineering and Materials Science and Engineering and Institute of Sustainability in Energy and Environment at the University of Illinois, Urbana-Champaign. He held a faculty position in Beckman Institute for Advanced Science and Technology, University of Illinois Cancer Center and Carle-Illinois College of Medicine. Pan’s lab uniquely merges fundamental chemistry, biology, and engineering to bring a solution to today’s healthcare problems. His research is highly collaborative and interdisciplinary centering on the development of novel materials for biomedical applications, immune-nanomedicine and targeted therapies for stem-like cancer cell with phenotypically screened nanomedicine platforms.

He holds multiple patents (8 granted US patents), several ongoing clinical trials and is the founder of three University-based early start-ups. He is the CEO/President for a biotechnology start-up Vitruvian Biotech dedicated to developing novel image-guided therapies. He also co-founded InnSight Technologies dedicated to nanotechnology-based application for ocular diseases.

• Education: MS, Vidyasagar University, India, PhD, Indian Institute of Technology (ITT) India
• Research: Postdoctoral Research, Washington University, St. Louis

Dr. Spinella is a well-established clinical trialist, who has been funded by the US Department of Defense and the National Institutes of Health. He has published over 245 manuscripts and 21 chapters and is the editor for a textbook on the topic of trauma resuscitation. Dr. Spinella has also participated in, organized research symposia for, or provided external review of research programs for the FDA, NIH, DoD, Homeland Security, and the Department of Health and Human Services. He has also participated on a committee for the National Academy of Sciences to develop recommendations for a national trauma system in the US.

Dr. Spinella co-founded the THOR Network and has been its Co-Director since 2011. The THOR network has hosted training and educational programs in over 12 countries in 4 continents. The THOR Network has also performed groundbreaking research related to whole blood and platelet transfusion for traumatic bleeding.